Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2019 | 12-2018 | 09-2018 | 12-2017 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -7,470 | -22,711 | -13,658 | -11,054 |
| Depreciation Amortization | 114 | 278 | 191 | 161 |
| Accounts payable and accrued liabilities | 1,821 | N/A | -192 | N/A |
| Other Working Capital | -1,433 | 2,179 | -448 | 443 |
| Other Operating Activity | -1,377 | 210 | 256 | 93 |
| Operating Cash Flow | $-8,345 | $-20,044 | $-13,851 | $-10,357 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -715 | -788 | -431 | -385 |
| Investing Cash Flow | $-715 | $-788 | $-431 | $-385 |
| Cash Flows From Financing Activities | ||||
| Change In Short Term Borrowing | 10,000 | N/A | 5,000 | N/A |
| Common Stock Issued | 10 | N/A | N/A | N/A |
| Other Financing Activity | 23 | 22,337 | 12,096 | 8,068 |
| Financing Cash Flow | $10,033 | $22,337 | $17,096 | $8,068 |
| Beginning Cash Position | 1,987 | 482 | 482 | 3,156 |
| End Cash Position | 2,960 | 1,987 | 3,296 | 482 |
| Net Cash Flow | $973 | $1,505 | $2,814 | $-2,674 |
| Free Cash Flow | ||||
| Operating Cash Flow | -8,345 | -20,044 | -13,851 | -10,357 |
| Capital Expenditure | -715 | N/A | -431 | N/A |
| Free Cash Flow | -9,060 | -20,044 | -14,282 | -10,357 |